Parallel Health launches custom phage protocol for hard-to-match skin bacteria

Parallel Health introduced CPD-01, a personalized phage development protocol designed for patients whose skin bacteria do not match the company’s existing biobanks. The San Francisco precision health company said the process can take three to 12 months and is overseen by dermatologists through its telehealth platform.

Why it matters: - Parallel Health is trying to move personalized skin care beyond standard matching to fully bespoke phage development. - The CPD-01 Protocol™ targets patients with uncommon or previously unidentified bacterial strains that may drive chronic skin issues or unique body odor cases. - The company said the new protocol is the next tier above its MD-03 Protocol™ when an existing phage is not available.

What happened: - Parallel Health announced the CPD-01 Protocol™ on Aug. 11, 2026. - The San Francisco-based precision health company described CPD-01 as a Custom Phage Development Protocol built from a single patient’s own bacteria. - The protocol isolates a patient’s bacterial strain and develops a unique phage aimed at the issue-causing bacteria. - Dr. Nathan Brown, co-founder and chief science officer, said the protocol creates a “brand new key” when Parallel’s biobank does not contain a match.

The details: - Parallel’s MD-03 Protocol™ uses a three-step model: test and discover the skin microbiome, collaborate on clinical care, and provide a custom compounded prescription and/or phage serum matched from the company’s biobanks. - CPD-01 is reserved for cases where no biobank match exists. - The scientific team isolates the bacteria directly from the patient before developing the phage. - The development and formulation process can take three to 12 months, depending on the target bacteria. - The end product is a personalized cosmeceutical topical made for one person’s biology. - Parallel said the protocol can support acne, rosacea, melasma, hidradenitis suppurativa, and other unexplained skin issues that are determined to be microbially driven through its quantitative skin microbiome test. - In California, Parallel is in-network with Aetna, Cigna, UnitedHealthcare and Blue Shield of California. - Patients may be eligible for insurance coverage depending on medical evaluation and clinical situation. - Eligibility for CPD-01 is determined through clinical evaluation. - Every CPD-01 case is reviewed and guided by a dermatologist from initial testing through formulation.

Between the lines: - Parallel is betting that more cases will justify more custom development as its phage biobank expands. - The company said each new case adds to the biobank and is expected to shorten CPD-01 timelines over time. - The launch also underscores a broader push to make precision medicine more practical in dermatology through telehealth and microbiome testing.

What’s next: - Parallel Health will keep expanding its phage biobank as it sees more patients. - The company expects larger case volume to reduce the time needed to complete future CPD-01 protocols. - Parallel’s clinician-led telehealth model remains the delivery channel for both MD-03 and CPD-01 cases.

The bottom line: - Parallel Health is adding a deeper layer of personalization for patients whose skin bacteria are too unusual for its current library, but the tradeoff is a much longer development timeline.